NV-5138 NEW
| Price | $91 | $226 | $363 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: NV-5138 | CAS No.: 2095886-80-7 |
| Purity: ≥98% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | NV-5138 |
| Description | NV-5138 is a selective, orally active intracerebral mTORC1 agonist that binds to Sestrin2. It is a leucine analog. It can be used in biological studies of antidepressants. |
| In vivo | METHODS: Rats were orally administered NV-5138 (40, 80 or 160 mg/kg), and behavioral tests were started 24 hours later, including behavioral despair test (forced swimming test FST) and anxiety test (novelty suppression feeding test NSFT). In FST and NSFT, analyzes were performed 1 or 3 days after dosing. RESULTS NV-5138 significantly reduced immobility time and feeding latency, respectively, at 160 mg/kg but not at 40 or 80 mg/kg. [1] METHODS: To test the duration of the antidepressant effect of NV-5138, rats were orally administered NV-5138 (160 mg/kg) and behavioral tests were started after 3 and 7 days or daily administration for 7 days (starting on day 0 ) of lower doses of NV-5138 (40 or 80 mg/kg, oral) RESULTS NV-5138 significantly reduced immobility time at both 3 and 7 days after FST administration; NV-5138 produced antidepressant effects at repeated low doses of NV-5138 (80mg/kg). [1] |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 1.81 mg/ml (10 mM) |
| Keywords | NV-5138 | inhibit | Inhibitor | NV5138 | mTOR | Mammalian target of Rapamycin | NV 5138 |
| Inhibitors Related | α-Hydroxyglutaric Acid Lithium | L-Leucine | Capivasertib | Sapanisertib | Everolimus | Bimiralisib | Salidroside | Tacrolimus | GDC0084 | TMBIM6 antagonist-1 | Dihydromyricetin | Rapamycin |
| Related Compound Libraries | Neural Regeneration Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Neuroprotective Compound Library | Anti-Aging Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $862.00/25mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $1980.00/50mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
| $91.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-19 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY